LIVE
WDC$260.94-32.84 (-11.18%)|GOOGL$265.56-8.34 (-3.04%)|INTC$51.34-3.78 (-6.86%)|ORCL$101.11-8.90 (-8.09%)|AMD$423.55-57.50 (-11.95%)|NVO$37.81-1.08 (-2.78%)|JNJ$270.90+4.90 (+1.84%)|NOC$534.11-4.44 (-0.82%)|AVGO$304.02-42.98 (-12.39%)|MRVL$121.89-16.41 (-11.87%)|TSLA$346.25-26.52 (-7.11%)|VST$115.16-6.84 (-5.61%)|VRT$166.15-16.55 (-9.06%)|TSM$319.17-30.93 (-8.83%)|TER$204.52-19.58 (-8.74%)|SMCI$21.66-2.04 (-8.61%)|RCL$296.49-5.81 (-1.92%)|QBTS$6.49-0.82 (-11.22%)|OKLO$20.00+ (+%)|NVDA$125.90-19.77 (-13.57%)|WDC$260.94-32.84 (-11.18%)|GOOGL$265.56-8.34 (-3.04%)|INTC$51.34-3.78 (-6.86%)|ORCL$101.11-8.90 (-8.09%)|AMD$423.55-57.50 (-11.95%)|NVO$37.81-1.08 (-2.78%)|JNJ$270.90+4.90 (+1.84%)|NOC$534.11-4.44 (-0.82%)|AVGO$304.02-42.98 (-12.39%)|MRVL$121.89-16.41 (-11.87%)|TSLA$346.25-26.52 (-7.11%)|VST$115.16-6.84 (-5.61%)|VRT$166.15-16.55 (-9.06%)|TSM$319.17-30.93 (-8.83%)|TER$204.52-19.58 (-8.74%)|SMCI$21.66-2.04 (-8.61%)|RCL$296.49-5.81 (-1.92%)|QBTS$6.49-0.82 (-11.22%)|OKLO$20.00+ (+%)|NVDA$125.90-19.77 (-13.57%)|

Datenschutz & Cookies

Wir nutzen Cookies, um diese Website zu betreiben und zu verbessern. Einige sind technisch notwendig, andere helfen uns, die Nutzung zu verstehen. Du kannst frei wählen, welche du erlaubst. Datenschutz

Novo Nordisk

NVO·NYSE
Analysis date:November 21, 2026
Current price
$37.81-1.08(-2.78%)
52W High:$64.16
|
52W Low:$35.12

NextSignal Score™

AI-powered rating

52of 100
Neutral
Fundamentals
18
Max: 25
Positive
Valuation
20
Max: 25
Low
Risk
5
Max: 20
High
Trend
4
Max: 15
Negative
Momentum
5
Max: 15
Weak
Market assessment NVO
Key signals
No entry recommended
Avoid risk
Stock is under pressure – caution advised on entry.
Price
$37.81
Target Zone
$40*
Support
$37
Analysts
Hold
Conclusion
The technical situation remains challenging with a bearish trend and prices below the key moving averages. Combined with the neutral NextSignal Score of 52/100, a wait-and-see approach is advisable until a more stable bottoming process emerges.
*Target zone is an analyst estimate and provides no guarantee that this level will be reached.

Stock Analysis Summary

18/25
Fundamentals

Moderates Umsatzwachstum, Positives EPS-Wachstum, Hohe Bruttomarge, Starke Eigenkapitalrendite.

20/25
Valuation

KGV 11.5 – günstig, KUV attraktiv, KBV attraktiv, Analysten neutral.

5/20
Risk

Negativer Trend, Beta 1.85 – hohe Volatilität.

4/15
Trend

Abwärtstrend aktiv.

5/15
Momentum

RSI 44.8 – neutrales Momentum.

Analyst Consensus36 Analysts · 2026-11-01
Hold
36
Analysts
Buy
28%
Hold
56%
Sell
17%

Novo Nordisk stock is currently trading at $37.82, placing it in a phase of technical consolidation.

🚀 What is happening currently?

Novo Nordisk is in a complex transformation phase, as the company attempts to regain lost ground by diversifying its pipeline and expanding its Wegovy pill business. Recent clinical data, such as that for CagriSema and the use of Wegovy in children, underscore the group's medical innovation power. Nevertheless, the market environment remains characterized by intense competition and pricing pressure on GLP-1 preparations. Investors are currently watching closely to see whether the raised annual forecast and operational discipline are sufficient to initiate a sustainable recovery, while the increased risk posed by the patent expiration of semaglutide in 2032 remains in focus.

🔍 Technical Analysis

At a price of $37.82, the stock is trading significantly below the EMA20 ($39.97), the EMA50 ($40.62), and the EMA200 ($45.09), confirming the overarching downward trend. The 52-week high is at $64.16, while the 52-week low of $35.12 represents an important psychological level. The RSI of 38.6 signals a neutral to slightly weak condition without reaching oversold territory. As the MACD (-0.100) is below its signal (0.160), momentum continues to weaken. The next support levels are at $$36.85,35.85, and $35.12, while resistance levels are forming at $$39.88,43.24, and $46.05.

📊 Fundamental Situation

The company has adjusted its forecast for 2026 several times and now expects adjusted revenue and operating profit to fluctuate between a 2% decline and 2% growth. The quarterly figures for the third quarter of 2026 showed a solid operational performance, although the stock is driven more by long-term future expectations than by current profitability. Fundamental data is partially incomplete and should be interpreted with caution, as the effects of US pricing and pipeline development costs are influencing margins.

🎯 Analyst Expectations

The average analyst price target is $45.73, implying an upside potential of approximately 20.92%. The consensus analyst rating is "Hold," reflecting a cautious stance on short-term price performance.

💡 Market Assessment

The NextSignal Score of 52/100 rates the stock as neutral. This evaluation reflects the discrepancy between positive clinical progress and the technically damaged condition. As the price remains below the key moving averages, no clear trend is currently discernible. Investors should wait for further developments in margins and the market launch of new products before assuming a trend reversal. A neutral position seems appropriate given the current data.

🔍 What to watch for

  1. US pricing trends: The effects of price pressure on injectable GLP-1 preparations in the US are crucial for margin development.
  2. CagriSema approval: The FDA's decision on the approval of CagriSema is a key milestone for the pipeline strategy.
  3. 2027 quarterly figures: The upcoming results on 03.02.2027 will show whether the operational recovery is gaining momentum.

Technical analysis

Last 60 trading days · Live data from Yahoo Finance

Price Chart + EMA 20 / 50 / 200
28.0814.0928.0912.1026.1009.11$37$41$45$49
2026-11-20
Kurs37.82
EMA 2039.97
EMA 5040.62
EMA 20045.09
Kurs
EMA 20
EMA 50
EMA 200
RSI (14)
28.0814.0928.0912.1026.1009.1102550100OBOS
2026-11-20
RSI38.58
MACD
28.0814.0928.0912.1026.1009.11-2.25-1.5-0.750.75
2026-11-20
Histogramm-0.26
MACD-0.10
Signal0.16
What does the chart show?
  • • Price action over the last few weeks at a glance.
  • • EMA lines help identify the prevailing trend direction.

Fundamentals & News

Live data